Biotech columnist Adam Feuerstein answers readers' questions about health care.
Sales of MannKind's inhaled insulin Afrezza totaled €1 million in the first quarter of its commercial launch.
Sanofi reports first-quarter earnings on Thursday morning, but it's unclear if sales of the recently launched inhaled insulin medication Afrezza will be disclosed.
Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.
Will the FDA bring together DMD experts for a single meeting to review both BioMarin's drisapersen and Sarepta's eteplirsen, or will two separate meetings be scheduled?
Overall, Bristol sales in the March quarter were $4 billion, a 6% increase from one year ago and higher than consensus.
On an adjusted basis, Merck reported first quarter earnings per share of 85 cents, topping the Street consensus of 74 cents per share.
Will the failure of Celladon's Mydicar gene therapy bring other high-flying gene therapy stocks down to Earth?
Catalyst and Jacobus Pharma are racing to secure FDA approval for a drug to treat a rare muscle-wasting disease.
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.